A pioneering digital therapeutics company delivering app-based prescription treatments for chronic diseases.
CureApp, Inc. develops and commercializes evidence-based digital therapy solutions delivered via mobile applications. By combining clinical evidence, behavioral science, and real-time analytics, CureApp supports patients and doctors in the treatment of conditions such as nicotine addiction, hypertension, and nonalcoholic steatohepatitis (NASH). CureApp’s healthcare apps are prescribed by medical professionals and subject to regulatory approval, advancing digital medicine alongside traditional therapies.
competitors.competitorDetail.metrics.missionStatement
To advance medicine by leveraging technology, providing the next era of disease treatments with scientifically-validated digital therapeutics.
competitors.competitorDetail.metrics.visionStatement
To establish digital therapeutics as a new pillar of global medical care, empowering better outcomes for chronic conditions worldwide.
competitors.competitorDetail.metrics.foundedYear
2014
competitors.competitorDetail.metrics.ceo
Kohta Satake
competitors.competitorDetail.metrics.employees
100-200
competitors.competitorDetail.metrics.revenue
$10M - $20M
competitors.competitorDetail.metrics.headquarters
Higashi 1-1-1, Shibuya-ku, Tokyo, Japan
competitors.competitorDetail.metrics.marketShare
Market leader in digital therapeutics for nicotine addiction in Japan; growing presence in Asia.
competitors.competitorDetail.metrics.usp
First-to-market, regulatory-approved digital therapeutics apps in Asia, developed and validated in partnership with world-class hospitals.
competitors.competitorDetail.metrics.pricingModel
Prescription-based, reimbursed by healthcare systems or insurers (B2B2C); SaaS for clinics and hospitals.
- CureApp SC (for nicotine addiction)
- CureApp HT (for hypertension)
- CureApp NASH (for nonalcoholic steatohepatitis)
- React Native
- Amazon Web Services
- Python
- AI/ML for personalized treatment
- Secure Health Data APIs
competitors.competitorDetail.metrics.marketPositioning
Regulatory-approved companion for chronic disease management; trusted partner for hospitals and insurers.
- Hospitals & clinics specializing in chronic disease
- Smokers seeking tobacco cessation
- Hypertensive patient groups
- Health insurers integrating digital health
- Hospitals and clinics
- Healthcare provider networks
- Pharmaceutical partnerships
- Direct to patients (regulated markets)
- Medical conferences and journals
- Provider and hospital outreach
- Clinical trial publications
- Health system partnerships
- Digital health webinars
- Keio University Hospital (Clinical Collaboration)
- Sumitomo Dainippon Pharma (Drug Companion App Partnership)
- App-based prescription digital therapeutics (DTx)
- Clinician dashboards and remote monitoring
- Personalized behavior modification programs
- Integration with wearable devices
- Clinical trial and reimbursement support
- Clinically-validated therapies
- Regulatory-approved digital medicine
- Strong hospital and academic partnerships
- Experienced multidisciplinary team
- Limited international market reach
- Lengthy regulatory approval processes
- Dependent on healthcare provider adoption
- Expansion into U.S. and EU healthcare markets
- Broader drug-companion app partnerships
- Rising demand for at-home therapy post-COVID
- Emerging DTx competitors
- Changing digital health regulations
- Healthcare data privacy concerns
competitors.competitorDetail.metrics.growthRateYOY
40%
competitors.competitorDetail.metrics.profitMargin
20%
competitors.competitorDetail.metrics.customerAcquisitionCost
$500-$800 per provider
competitors.competitorDetail.metrics.customerLifetimeValue
$10,000+ per hospital/clinic partner
competitors.competitorDetail.metrics.churnRate
2% quarterly (provider contracts)
| competitors.competitorDetail.metrics.fundingStage | competitors.competitorDetail.metrics.fundingAmount | competitors.competitorDetail.metrics.fundingDate |
|---|---|---|
| Series A | $3.5M | 2016-03-20 |
| Series B | $7.7M | 2019-03-01 |
| Series C | $16M | 2021-12-21 |
- Strong emphasis on scientific research
- Mission-driven innovation
- Cross-disciplinary collaboration
- Patient outcome focus
- Agile and transparent decision-making
- Minister of Economy, Trade and Industry Award (Japan Healthcare Business Contest) (2018) - Japanese Government
- Forbes Japan Startup of the Year (2021) - Forbes Japan
| competitors.competitorDetail.reviews.title | competitors.competitorDetail.reviews.rating | competitors.competitorDetail.reviews.viewAll |
|---|---|---|
| Google Play | 4.3/5 | 500 |
| App Store | 4.2/5 | 340 |
| competitors.competitorDetail.news.title | competitors.competitorDetail.news.publishedOn | competitors.competitorDetail.news.readMore |
|---|---|---|
| CureApp's Digital Therapy for Hypertension Gains Regulatory Approval in Japan | 2022-09-08 | Nikkei Asia |
| Sumitomo Dainippon Pharma and CureApp Announce Strategic Alliance on Digital Health | 2023-01-17 | BusinessWire |